🔗 Share this article

While America continues making sweeping adjustments to its vaccine schedules, one figure has emerged unexpectedly: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by questioning Covid vaccines during the global health crisis and has concentrated on possible deaths following COVID-19 vaccination in her recent position at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Vaccine Program

Agency leaders had intended to announce radical revisions to the childhood immunization program recently, bringing the US with Denmark’s immunization schedule, it is understood – a major change that would place the US at odds with much of the international standard with no evidence for improved outcomes. This reveal has been postponed until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is set to present at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the division this year.

Consolidating Power at the FDA

This interim role could signify a closer partnership between the drug and vaccine centers as Dr. Høeg and Prasad solidify control at the regulatory agency – and it signals a greater focus upon reevaluating previously authorized vaccines at the FDA.

Høeg has often pushed for ending some pediatric immunization guidelines in the US to become more similar to the Danish model, a society with universal health coverage and a citizenry approximately the population of the state of Wisconsin.

So far statements, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – instead of medication approval.

Concerns Over Background

Høeg has no apparent experience in medication creation, approval processes or management, which has been customary for past heads of the biologics center. She has been employed at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“She appears not to have any of the qualifications” for leading the CDER, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in managing a large organization. She lacks background in pharmaceutical oversight.”

Previous commissioners of the center would “understand legal statutes and the science of drug development”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that former directors who ran CBER have had.”

CDER has an immense portfolio at the FDA, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the generic drug division approves thousands of generic drugs. There’s a biosimilars program, non-prescription drug unit and more, and every single one need to be looked after,” Dr. Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership component to the job, which supervises over 5,000 employees. “It’s a massive leadership role, if you execute it properly,” the former official added.

Agency Reaction and Disputed Initiatives

Regarding inquiries about Dr. Høeg's fitness for the role and whether this selection represents increased cooperation among agency officials on vaccines, a press secretary stated that the “inquiries are based on inaccurate premises”.

“Her experience is consistent with the duties of her job,” the spokesperson stated, citing the months Dr. Høeg spent advising the agency head on “medication safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a contentious one-day medication authorization process that apparently troubled her predecessors. “By what process are these drugs being selected for this expedited pathway? Who is making the calls?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the agency right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards laxer oversight of pharmaceuticals, with the exception of vaccines.”

Established Past Work on Immunizations

Regarding immunizations, Høeg has a clearer, if troubling, past, some experts observe. She released a analysis using unverified public submissions to estimate the incidence of heart inflammation following COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to suggest Covid vaccines are more dangerous than they are.

Included in her “desired changes” for the current administration featured changing rules for recently developed shots and halting “non-essential” vaccines, she said following the vote on a podcast. At the agency, Dr. Høeg has according to sources proposed preventing teenage boys from getting COVID-19 vaccines.

“She is an all-around dogmatist who begins with her preconceived notions and reverse-engineers to accommodate the evidence in a very disingenuous, dishonest fashion,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Høeg aligned with fellow contrarians, {like|